177 related articles for article (PubMed ID: 23071629)
41. Osteoclast resorption of beta-tricalcium phosphate controlled by surface architecture.
Davison NL; ten Harkel B; Schoenmaker T; Luo X; Yuan H; Everts V; Barrère-de Groot F; de Bruijn JD
Biomaterials; 2014 Aug; 35(26):7441-51. PubMed ID: 24927681
[TBL] [Abstract][Full Text] [Related]
42. (Pre-)osteoclasts induce retraction of osteoblasts before their fusion to osteoclasts.
Perez-Amodio S; Beertsen W; Everts V
J Bone Miner Res; 2004 Oct; 19(10):1722-31. PubMed ID: 15355568
[TBL] [Abstract][Full Text] [Related]
43. Effects of cobalt and chromium ions at clinically equivalent concentrations after metal-on-metal hip replacement on human osteoblasts and osteoclasts: implications for skeletal health.
Andrews RE; Shah KM; Wilkinson JM; Gartland A
Bone; 2011 Oct; 49(4):717-23. PubMed ID: 21689801
[TBL] [Abstract][Full Text] [Related]
44. An assay system utilizing devitalized bone for assessment of differentiation of osteoclast progenitors.
Amano S; Hanazawa S; Kawata Y; Ohta K; Kitami H; Kitano S
J Bone Miner Res; 1992 Mar; 7(3):321-8. PubMed ID: 1585834
[TBL] [Abstract][Full Text] [Related]
45. Human osteoclast formation and activity on a xenogenous bone mineral.
Perrotti V; Nicholls BM; Horton MA; Piattelli A
J Biomed Mater Res A; 2009 Jul; 90(1):238-46. PubMed ID: 18496862
[TBL] [Abstract][Full Text] [Related]
46. The role of osteoclasts in bone tissue engineering.
Detsch R; Boccaccini AR
J Tissue Eng Regen Med; 2015 Oct; 9(10):1133-49. PubMed ID: 24478169
[TBL] [Abstract][Full Text] [Related]
47. The biodegradation of hydroxyapatite bone graft substitutes in vivo.
Rumpel E; Wolf E; Kauschke E; Bienengräber V; Bayerlein T; Gedrange T; Proff P
Folia Morphol (Warsz); 2006 Feb; 65(1):43-8. PubMed ID: 16783735
[TBL] [Abstract][Full Text] [Related]
48. Calcitonin receptors as markers for osteoclastic differentiation: correlation between generation of bone-resorptive cells and cells that express calcitonin receptors in mouse bone marrow cultures.
Hattersley G; Chambers TJ
Endocrinology; 1989 Sep; 125(3):1606-12. PubMed ID: 2547591
[TBL] [Abstract][Full Text] [Related]
49. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
Kupisiewicz K
Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
[TBL] [Abstract][Full Text] [Related]
50. How to Get Them off?-Assessment of Innovative Techniques for Generation and Detachment of Mature Osteoclasts for Biomaterial Resorption Studies.
Heinemann C; Adam J; Kruppke B; Hintze V; Wiesmann HP; Hanke T
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33572748
[TBL] [Abstract][Full Text] [Related]
51. Inhibition of bone resorption by inorganic phosphate is mediated by both reduced osteoclast formation and decreased activity of mature osteoclasts.
Yates AJ; Oreffo RO; Mayor K; Mundy GR
J Bone Miner Res; 1991 May; 6(5):473-8. PubMed ID: 2068953
[TBL] [Abstract][Full Text] [Related]
52. Titanium particles stimulate bone resorption by inducing differentiation of murine osteoclasts.
Bi Y; Van De Motter RR; Ragab AA; Goldberg VM; Anderson JM; Greenfield EM
J Bone Joint Surg Am; 2001 Apr; 83(4):501-8. PubMed ID: 11315778
[TBL] [Abstract][Full Text] [Related]
53. Formation of osteoclast-like cells on HA and TCP ceramics.
Detsch R; Mayr H; Ziegler G
Acta Biomater; 2008 Jan; 4(1):139-48. PubMed ID: 17723325
[TBL] [Abstract][Full Text] [Related]
54. Microcracks and osteoclast resorption activity in vitro.
Rumpler M; Würger T; Roschger P; Zwettler E; Peterlik H; Fratzl P; Klaushofer K
Calcif Tissue Int; 2012 Mar; 90(3):230-8. PubMed ID: 22271249
[TBL] [Abstract][Full Text] [Related]
55. Cyclosporin-A in vitro decreases bone resorption, osteoclast formation, and the fusion of cells of the monocyte-macrophage lineage.
Orcel P; Denne MA; de Vernejoul MC
Endocrinology; 1991 Mar; 128(3):1638-46. PubMed ID: 1999178
[TBL] [Abstract][Full Text] [Related]
56. Bovine dentine organic matrix down-regulates osteoclast activity.
Sriarj W; Aoki K; Ohya K; Takagi Y; Shimokawa H
J Bone Miner Metab; 2009; 27(3):315-23. PubMed ID: 19296049
[TBL] [Abstract][Full Text] [Related]
57. Influence of glucocorticoids on human osteoclast generation and activity.
Sivagurunathan S; Muir MM; Brennan TC; Seale JP; Mason RS
J Bone Miner Res; 2005 Mar; 20(3):390-8. PubMed ID: 15746983
[TBL] [Abstract][Full Text] [Related]
58. Joint fluid from patients with failed total hip arthroplasty stimulates pit formation by mouse osteoclasts on dentin slices.
Kim KJ; Hijikata H; Itoh T; Kumegawa M
J Biomed Mater Res; 1998; 43(3):234-40. PubMed ID: 9730060
[TBL] [Abstract][Full Text] [Related]
59. Peptidomimetic antagonists of alphavbeta3 inhibit bone resorption by inhibiting osteoclast bone resorptive activity, not osteoclast adhesion to bone.
Carron CP; Meyer DM; Engleman VW; Rico JG; Ruminski PG; Ornberg RL; Westlin WF; Nickols GA
J Endocrinol; 2000 Jun; 165(3):587-98. PubMed ID: 10828842
[TBL] [Abstract][Full Text] [Related]
60. Regulation of osteoclast differentiation and function by phosphate: potential role of osteoclasts in the skeletal abnormalities in hypophosphatemic conditions.
Hayashibara T; Hiraga T; Sugita A; Wang L; Hata K; Ooshima T; Yoneda T
J Bone Miner Res; 2007 Nov; 22(11):1743-51. PubMed ID: 17638577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
